Correlation Between NYSE Composite and Cardiol Therapeutics

Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Cardiol Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Cardiol Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NYSE Composite and Cardiol Therapeutics Class, you can compare the effects of market volatilities on NYSE Composite and Cardiol Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Cardiol Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Cardiol Therapeutics.

Diversification Opportunities for NYSE Composite and Cardiol Therapeutics

-0.76

Correlation Coefficient

NYSE Composite  Cardiol Therapeutics

Pay attention - limited upside

The 3 months correlation between NYSE and Cardiol is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Cardiol Therapeutics Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiol Therapeutics and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Cardiol Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiol Therapeutics has no effect on the direction of NYSE Composite i.e., NYSE Composite and Cardiol Therapeutics go up and down completely randomly.

Pair Corralation between NYSE Composite and Cardiol Therapeutics

Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.18 times more return on investment than Cardiol Therapeutics. However, NYSE Composite is 5.55 times less risky than Cardiol Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Cardiol Therapeutics Class is currently generating about -0.26 per unit of risk. If you would invest  1,925,638  in NYSE Composite on September 14, 2024 and sell it today you would earn a total of  47,299  from holding NYSE Composite or generate 2.46% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

NYSE Composite  vs.  Cardiol Therapeutics Class

Pair Trading with NYSE Composite and Cardiol Therapeutics

The main advantage of trading using opposite NYSE Composite and Cardiol Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Cardiol Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will offset losses from the drop in Cardiol Therapeutics' long position.

The idea behind NYSE Composite and Cardiol Therapeutics Class pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.